GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Johnson & Johnson JNJ · USD

Health Care · Pharmaceuticals · US listing · 🇺🇸 United States

S&P 500Dow Jones

Compare

276.22

+1.43%

Close of 6 Nov 2026, in USD

Price performance

Chart by TradingView, with its own licensed prices

Johnson & Johnson — daily JNJ Delayed
Market value
$665.66bn
Last close × shares
Volume
8.9m
Shares, 6 Nov 2026
Price to earnings
25.0
Dividend yield
1.91%

About Johnson & Johnson

From its filings with the US Securities and Exchange Commission

SEC filings

Johnson & Johnson is based in New Brunswick, New Jersey and is incorporated in New Jersey. Its shares trade on NYSE under the ticker JNJ. It is a member of the S&P 500 and Dow Jones. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 28 December 2025, it reported revenue of $94.19bn and net income of $26.80bn. At that date it held total assets of $199.21bn and shareholders' equity of $81.54bn. By region, United States accounted for 57.1%, followed by Non-US at 42.9%.

In its own words

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.

The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.

The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopaedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a wide range of acute and elective procedures. These products are designed to address disease states where procedural intervention plays a central role in treatment and patient outcomes.

Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗

More about Johnson & Johnson →

How it makes its money

Revenue, year to 28 Dec 2025

  • DARZALEX $14.35bn · 15.2%
  • Stelara $6.08bn · 6.5%
  • ELECTROPHYSIOLOGY $5.63bn · 6.0%
  • GENERAL $5.56bn · 5.9%

Latest on Johnson & Johnson

Our reporting

Next results

20 Jan 2027

Due on 20 Jan 2027. Analysts expect earnings of 2.91 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Johnson & Johnson's ticker?

Johnson & Johnson trades as JNJ on its US listing, under ISIN US4781601046.

What was Johnson & Johnson's last closing price?

276.22 on 6 Nov 2026. The figure is in USD and is never converted.

When does Johnson & Johnson next report results?

Results are expected on 20 Jan 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.